Key result
Long-term enalapril reduces left ventricular mass index by ~39% in hypertensive patients.
Why the study?
The effects of long-term angiotensin-converting enzyme inhibitor treatment for essential hypertension on resting and exercise arterial pressure, left ventricular mass, and functional sequelae needed to be determined.
Does long-term treatment with enalapril for 5 years reduce arterial pressure and left ventricular mass while preserving left ventricular systolic function in patients with previously untreated essential hypertension?
Cohort (n=26)
Does long-term treatment with enalapril for 5 years reduce arterial pressure and left ventricular mass while preserving left ventricular systolic function in patients with previously untreated essential hypertension?
Answers are grounded in this paper and cite their sources.
Long-term 5-year enalapril therapy progressively reduces left ventricular hypertrophy by 39% and improves left ventricular pump function, with structural and functional benefits persisting 8 weeks after drug withdrawal despite blood pressure returning to pre-treatment levels.
OBJECTIVES: To determine the effects of long-term treatment of essential hypertension with an angiotensin-converting enzyme inhibitor as regards arterial pressure at rest and during exercise, left ventricular mass and functional sequelae. PATIENTS AND METHODS: Twenty-six patients with previously untreated essential hypertension took enalapril 20 mg twice daily for 5 years. Cardiovascular parameters were determined by two-dimensionally guided M-mode echocardiography in a pre-treatment placebo phase, 8 weeks and 1, 3 and 5 years after the start of therapy, and 8 weeks after drugs were discontinued. RESULTS: Therapy reduced resting arterial pressure from 156/105 to 128/84 mmHg (P < 0.001) and arterial pressure during exercise from 205/113 to 172/94 mmHg (P < 0.0011). After 1, 3 and 5 years' therapy, left ventricular mass index had decreased by 15, 28 and 39% respectively (P < 0.001 in each case). Eight weeks after treatment was halted, arterial pressure at rest and during exercise had returned to pre-treatment values, but decreased left ventricular mass was maintained. Left ventricular pump function had improved after 5 years' treatment, and this improvement was maintained during the 8 weeks without treatment. CONCLUSIONS: Significant reductions in arterial pressure at rest and during exercise were achieved by 8 weeks' treatment with enalapril and maintained during 5 years' further treatment, while a marked reduction in left ventricular mass took place progressively throughout the 5 year period. Reduction of myocardial hypertrophy by enalapril appeared to be beneficial rather than detrimental to cardiac pump performance.
No takes yet. Share an insight, caveat, or question.
González‐Juanatey et al. (1995) conducted a cohort in previously untreated essential hypertension (n=26). Enalapril vs. Pre-treatment placebo phase (baseline) was evaluated on Left ventricular mass index reduction at 5 years (p=< 0.001). Enalapril twice daily for 5 years reduced left ventricular mass index by 39% and resting arterial pressure from 156/105 to 128/84 mmHg.
Synapse has enriched 10 related papers. Consider them for comparative context: